Literature DB >> 15200121

Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.

Yuichi Hirose1, Makoto Katayama, Mitchel S Berger, Russell O Pieper.   

Abstract

OBJECT: The Chk1 and p38 mitogen-activated protein kinase (MAPK) pathways play key roles in the G2 arrest caused by exposing glioma cells to temozolomide (TMZ). Although inhibition of either pathway sensitizes glioma cells to TMZ-induced cytotoxicity, the relative contributions of these pathways to TMZ-induced G2 arrest and to TMZ resistance conferred by G2 arrest have not been defined.
METHODS: The authors pharmacologically inhibited the Chk1 and/or p38 pathways in U87MG human glioma cells prior to and/or after exposure to TMZ; thereafter, effects on the TMZ-induced G2 arrest pathway and toxicity were monitored. The p38 inhibitor SB203580 or the Chk1 inhibitor UCN-01 or their combination blocked TMZ-mediated inactivation of cdc25C and cdc2, suggesting that p38 and Chk1 pathways work cooperatively and are both necessary to inactivate cdc25C and cdc2. Consistent with this idea, the inhibition of both Chk1 and p38 pathways did not lead to greater bypass of TMZ-induced G2 arrest or greater cytotoxicity than inhibition of either pathway alone. Inhibition of p38 did not alter TMZ-induced Chk1 activation/phosphorylation and vice versa, suggesting that p38 and Chk1 do not cooperatively bring about G2 arrest by reciprocal activation/phosphorylation. The two pathways, however, are not functionally identical; the Chk1 pathway was required for both the initiation and maintenance of TMZ-induced G2 arrest, whereas the p38 pathway played a role only in the initiation.
CONCLUSIONS: The Chk1 and p38 pathways cooperate to bring about TMZ-induced G2 arrest, and the inhibition of either pathway alone is sufficient to sensitize U87MG glioma cells to TMZ-induced cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15200121     DOI: 10.3171/jns.2004.100.6.1060

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

Review 1.  Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response?

Authors:  H Christian Reinhardt; Ian G Cannell; Sandra Morandell; Michael B Yaffe
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

2.  Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.

Authors:  Christine Billecke; Susan Finniss; Laura Tahash; Cathie Miller; Tom Mikkelsen; Nicholas P Farrell; Oliver Bögler
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

3.  Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells.

Authors:  Seema Gupta; Sabapathi Sathishkumar; Mansoor M Ahmed
Journal:  Pancreatology       Date:  2010-10-29       Impact factor: 3.996

4.  p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.

Authors:  Leina Ma; Jia Liu; Xinling Zhang; Jieqiong Qi; Wengong Yu; Yuchao Gu
Journal:  Med Oncol       Date:  2015-02-19       Impact factor: 3.064

5.  p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G(2) DNA damage checkpoint in human cancer cells.

Authors:  Mark S Phong; Robert D Van Horn; Shuyu Li; Gregory Tucker-Kellogg; Uttam Surana; Xiang S Ye
Journal:  Mol Cell Biol       Date:  2010-06-01       Impact factor: 4.272

Review 6.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

7.  Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses.

Authors:  Mark W Wagner; Long Shan Li; Julio C Morales; Cristi L Galindo; Harold R Garner; William G Bornmann; David A Boothman
Journal:  J Biol Chem       Date:  2008-05-14       Impact factor: 5.157

8.  The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.

Authors:  Takuro Hayashi; Kazuhide Adachi; Shigeo Ohba; Yuichi Hirose
Journal:  J Neurooncol       Date:  2013-08-13       Impact factor: 4.130

9.  The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.

Authors:  Peng-Hsu Chen; Chia-Hsiung Cheng; Chwen-Ming Shih; Kuo-Hao Ho; Cheng-Wei Lin; Chin-Cheng Lee; Ann-Jeng Liu; Cheng-Kuei Chang; Ku-Chung Chen
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

10.  Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.

Authors:  Maja T Tomicic; Ruth Meise; Dorthe Aasland; Nancy Berte; Rebekka Kitzinger; Oliver H Krämer; Bernd Kaina; Markus Christmann
Journal:  Oncotarget       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.